Microbot Medical stock trades at 0.95 euros Friday evening
Published on 10/30/2026 at 19:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCommercialization and intellectual property
- Microbot Medical develops and distributes the LIBERTY endovascular robotic system.
- The company said on October 20 that its global portfolio had reached 44 issued and 49 pending patents.
Microbot Medical stock traded at 0.95 euros on Lang & Schwarz at 7:18 p.m. CET on Friday, October 30, 2026.
Patent portfolio supports expansion
Microbot Medical develops and distributes the LIBERTY endovascular robotic system. In a press release dated October 20, the company said its global intellectual-property portfolio comprised 44 issued patents and 49 pending patents.
The company said commercialization was advancing across US and international markets. Its strategy includes expanding the commercial reach of LIBERTY through direct activity and international distribution arrangements.
Microbot Medical's latest public communications also point to continued customer and geographic expansion following the system's full market release. The company remains dependent on further adoption, procedure volumes and the conversion of commercial opportunities into revenue.
Investors can follow the real-time quote of Microbot Medical stock for the latest Lang & Schwarz indication.
Microbot Medical stock at a glance
- Company: Microbot Medical Inc.
- ISIN: US59503A2042
- Ticker: MBOT
- Home exchange: Nasdaq
- Lang & Schwarz quote: 0.95 euros on October 30, 2026 at 7:18 p.m. CET
- Intellectual property: 44 issued patents and 49 pending patents as of October 20, 2026
The broader US market environment is covered in current S&P 500 market reports.
